In BC patients, CEA and CA15-3 median levels were 2.39 ng/ml and 23.8 U/ml, respectively, compared to their median levels in the control group (1.4 ng/ml and 6.8 U/ml, at p = 0.155 and 0.0001, respectively) (Table 2). Here, CEACAM5 is linked to breast cancer.